Diclofenac Potassium Nets $3 Million in First Quarter of 2013

Diclofenac Potassium Nets $3 Million in First Quarter of 2013

Diclofenac Potassium CAS# 15307-81-0, also known as the brand name Zipsor, netted an astounding three million dollars in sales for the first quarter of 2013. Depomed Incorporated, who markets the NSAID, recently reported their better than expected financials regarding this efficacious treatment for arthritis and pain. The patent for Zipsor expires on July 15, 2019, and the latest profits for Zipsor have folks in the R&D industry quite excited. Aimed at treating patients with osteoarthritis and rheumatoid arthritis, Diclofenac Potassium has proven to be an effectual, safe and tolerable nonsteroidal anti-inflammatory drug.

Patients pronDiclofenac-Potassiume to bleeding incidents, such as ulcers or intestinal bleeding may not be a candidate for treatment with Diclofenac Potassium. Additionally those patients who have clotting disorders or take blood thinners such as warfarin should not be administered Diclofenac Potassium. Many patients find that taking Diclofenac alongside food or milk helps their stomach to not get upset. Serious adverse effects from Diclofenac Potassium are rare, and common side effects may include diarrhea, nausea and ringing in the ears.

The myth that arthritis affects only the elderly people is still perpetrated in the United States, when in fact the opposite is actually true. Approximately two-thirds of American people diagnosed with arthritis are under 65 years of age! In addition, over 300,000 children have been diagnosed with a form of arthritis in the United States. These staggering statistics from Arthritis.org only reinforce the need for a greater number of medications and affordable treatments for this growing patient population.

LGM Pharma provides Diclofenac Potassium for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service